To validate the tumor-suppressive and bone-protective effects of LRP5-overexpressing osteocyte-derived CM in vivo, we established syngeneic mammary tumor and tibial bone metastasis models in C57BL/6 mice. The gene discussed is LRP5; the disease is breast cancer.